Moderna/$MRNA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Ticker
- $MRNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,700
- Headquarters
- Cambridge, United States
- Website
- www.modernatx.com
Moderna Metrics
BasicAdvanced
$79B
-
-$7.03
1.17
-
Price and volume
Market cap
$79B
Beta
1.17
52-week high
$280.80
52-week low
$22.28
Average daily volume
14M
Financial strength
Current ratio
3.621
Quick ratio
3.224
Long term debt to equity
0.611
Total debt to equity
0.611
Interest coverage (TTM)
-32.90%
Profitability
EBITDA (TTM)
-1,783
Gross margin (TTM)
-42.02%
Net profit margin (TTM)
-110.46%
Operating margin (TTM)
-80.79%
Effective tax rate (TTM)
-2.20%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-9.96%
Return on equity (TTM)
-34.50%
Valuation
Price to revenue (TTM)
30.621
Price to book
11.52
Price to tangible book (TTM)
11.79
Price to free cash flow (TTM)
-37.827
Free cash flow yield (TTM)
-2.64%
Free cash flow per share (TTM)
-5.155
Growth
Revenue change (TTM)
13.13%
Earnings per share change (TTM)
-12.57%
3-year revenue growth (CAGR)
-34.83%
3-year earnings per share growth (CAGR)
-8.02%
What the Analysts think about Moderna
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Analyst projections of the future price of Moderna stock.
Bulls say / Bears say
Third-quarter revenue rose 29% to $1.3 billion, and Moderna lifted its 2026 revenue-growth forecast to 15%–25%. Stronger international COVID vaccine sales and government partnerships are helping support the recovery. (SEC)
In a Phase 3 melanoma trial, intismeran plus Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. The result gives Moderna a potentially valuable oncology product, although regulatory approval is still ahead. (Moderna)
The FDA approved mFLUSIVA for adults aged 50 and over, making it the first approved mRNA seasonal flu vaccine. Its late approval means this season’s US launch is limited, but it adds a new product to Moderna’s respiratory vaccine portfolio. (Reuters)
Moderna remains heavily reliant on COVID vaccines: they generated $1.68 billion of its $1.72 billion in product sales in the first nine months of 2026. That leaves the business exposed if COVID vaccine demand weakens before newer products contribute meaningfully. (SEC)
The company used $2.7 billion of operating cash in the first nine months of 2026, and expects annual cash costs of $4 billion to $4.5 billion through 2030. Convertible-note financing has bolstered liquidity, but adds debt and possible dilution while substantial spending continues. (Yahoo Finance)
Moderna’s Phase 3 norovirus vaccine trial did not meet the criteria for early success, and the company is not adding another cohort this season while it consults regulators. The delay leaves the programme’s path forward uncertain. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 18 Nov 2026.
Moderna Financial Performance
Revenues and expenses
Moderna Earnings Performance
Company profitability
Upcoming events
No upcoming events
Moderna News
AllArticlesVideos
Funds containing Moderna
AllUSDEURGBP
Fund name | Fund size | $MRNA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 5.38% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 5.38% |
iShares Healthcare Innovation$HEAL | $1.6B | 5.14% |
iShares Healthcare Innovation£DRDR | $1.6B | 5.14% |
iShares Healthcare Innovation€2B78 | $1.6B | 5.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


